{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:47:37Z","timestamp":1740181657154,"version":"3.37.3"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T00:00:00Z","timestamp":1714867200000},"content-version":"vor","delay-in-days":125,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.prdoa.2024.100256","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T15:59:12Z","timestamp":1715011152000},"page":"100256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis"],"prefix":"10.1016","volume":"10","author":[{"given":"Stuart H.","family":"Isaacson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Pagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Abler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6995-8936","authenticated-orcid":false,"given":"Daniel","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2024.100256_b0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","article-title":"Prevalence of Parkinson's disease across North America","volume":"4","author":"Marras","year":"2018","journal-title":"NPJ Parkinsons. Dis."},{"issue":"4","key":"10.1016\/j.prdoa.2024.100256_b0010","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000445751","article-title":"The incidence of Parkinson's disease: A systematic review and meta-analysis","volume":"46","author":"Hirsch","year":"2016","journal-title":"Neuroepidemiology"},{"issue":"4","key":"10.1016\/j.prdoa.2024.100256_b0015","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"14","key":"10.1016\/j.prdoa.2024.100256_b0020","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/WNL.0b013e3181f61311","article-title":"What predicts mortality in Parkinson disease? A prospective population-based long-term study","volume":"75","author":"Forsaa","year":"2010","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.prdoa.2024.100256_b0025","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","article-title":"A 12-year population-based study of psychosis in Parkinson disease","volume":"67","author":"Forsaa","year":"2010","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.prdoa.2024.100256_b0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2217\/nmt-2017-0028","article-title":"Parkinson's disease psychosis: presentation, diagnosis and management","volume":"7","author":"Schneider","year":"2017","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.prdoa.2024.100256_b0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-3-319-95360-1_29","article-title":"Genetic Factors Influencing the Development and Treatment of Cognitive Impairment and Psychosis in Parkinson\u2019s Disease","volume":"III","author":"Perez-Lloret","year":"2019","journal-title":"Psychiatry and Neuroscience Update: from Translational Research to a Humanistic Approach-Volume"},{"key":"10.1016\/j.prdoa.2024.100256_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/2735361","article-title":"Motor\/nonmotor symptoms and progression in patients with Parkinson\u2019s disease: prevalence and risks in a longitudinal study","volume":"2020","author":"Yoritaka","year":"2020","journal-title":"Parkinson's Disease"},{"issue":"8","key":"10.1016\/j.prdoa.2024.100256_b0045","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS","volume":"22","author":"Ravina","year":"2007","journal-title":"NIMH Work Group. Mov Disord"},{"issue":"5","key":"10.1016\/j.prdoa.2024.100256_b0050","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archneur.63.5.713","article-title":"The malignant course of \u201cbenign hallucinations\u201d in Parkinson disease","volume":"63","author":"Goetz","year":"2006","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.prdoa.2024.100256_b0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mds.23462","article-title":"The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease","volume":"26","author":"Martinez-Martin","year":"2011","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.prdoa.2024.100256_b0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000129843.15756.A3","article-title":"Psychiatric comorbidities in patients with Parkinson disease and psychosis","volume":"63","author":"Marsh","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.prdoa.2024.100256_b0065","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/jnnp.67.3.300","article-title":"The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years","volume":"67","author":"Hely","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.prdoa.2024.100256_b0070","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3233\/JPD-213035","article-title":"Incidence, prevalence, and mortality of psychosis associated with parkinson disease (1991\u20132010)","volume":"12","author":"Stang","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.prdoa.2024.100256_b0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.parkreldis.2019.10.018","article-title":"Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study","volume":"68","author":"Wetmore","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"issue":"6","key":"10.1016\/j.prdoa.2024.100256_b0080","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/mds.22839","article-title":"The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria","volume":"25","author":"Fenelon","year":"2010","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.prdoa.2024.100256_b0085","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","article-title":"Pathophysiology and treatment of psychosis in Parkinson's disease: a review","volume":"25","author":"Zahodne","year":"2008","journal-title":"Drugs Aging"},{"issue":"12","key":"10.1016\/j.prdoa.2024.100256_b0090","doi-asserted-by":"crossref","first-page":"e1620","DOI":"10.1212\/WNL.0000000000011632","article-title":"Association of dementia-related psychosis with long-term care use and death","volume":"96","author":"Wetmore","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.prdoa.2024.100256_b0095","doi-asserted-by":"crossref","unstructured":"T.A.G.S.B.C.U.E. Panel, American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older Adults, J Am Geriatr Soc 67 (4) (2019) 674\u2013694.","DOI":"10.1111\/jgs.15767"},{"issue":"10","key":"10.1016\/j.prdoa.2024.100256_b0100","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/brainsci12101286","article-title":"Pimavanserin and Parkinson\u2019s disease psychosis: a narrative review","volume":"12","author":"Rissardo","year":"2022","journal-title":"Brain Sci."},{"issue":"1","key":"10.1016\/j.prdoa.2024.100256_b0105","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3390\/ijerph19010364","article-title":"Systematic Review on Parkinson\u2019s Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson\u2019s Symptoms","volume":"19","author":"Sivanandy","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.prdoa.2024.100256_b0110","unstructured":"CLOZARIL (clozapine), [package insert]. Rosemont, PA. HLS Therapeutics (USA), Inc.: 2023. 2023."},{"issue":"1","key":"10.1016\/j.prdoa.2024.100256_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-14-102","article-title":"Clozapine: a review of clinical practice guidelines and prescribing trends","volume":"14","author":"Warnez","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"9","key":"10.1016\/j.prdoa.2024.100256_b0120","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40263-016-0352-5","article-title":"Antipsychotic drug-induced somnolence: incidence, mechanisms, and management","volume":"30","author":"Fang","year":"2016","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.prdoa.2024.100256_b0125","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2024.100256_b0130","unstructured":"US Food and Drug Administration. FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. 2005 May 13, 2022]; Available from: http:\/\/psychrights.org\/drugs\/FDAantipsychotics4elderlywarning.htm."},{"key":"10.1016\/j.prdoa.2024.100256_b0135","unstructured":"US Food and Drug Administration. FDA alert on antipsychotics. 2008 May 13, 2022]; Available from: http:\/\/www.canhr.org\/newsroom\/newdev_archive\/2009\/FDA-Alert-on-Antipsychotics.pdf."},{"key":"10.1016\/j.prdoa.2024.100256_b0140","unstructured":"NUPLAZID (pimavanserin), [package insert]. San Diego, CA USA: Acadia Pharmaceuticals Inc., 2023."},{"issue":"Suppl. 1","key":"10.1016\/j.prdoa.2024.100256_b0145","first-page":"2","article-title":"Spotlight debate-should we worry that pimavanserin might increase mortality amongst patients with Parkinson's diseae psychosis? US","volume":"15","author":"Weintraub","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.prdoa.2024.100256_b0150","unstructured":"Acadia, Data on File."},{"issue":"5","key":"10.1016\/j.prdoa.2024.100256_b0155","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamaneurol.2016.0031","article-title":"Association of antipsychotic use with mortality risk in patients with Parkinson disease","volume":"73","author":"Weintraub","year":"2016","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.prdoa.2024.100256_b0160","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study","volume":"17","author":"Ballard","year":"2018","journal-title":"The Lancet Neurology"},{"issue":"suppl 2","key":"10.1016\/j.prdoa.2024.100256_b0165","article-title":"Parkinson's Disease Psychosis Associated Comorbidities, and Mortality in the Medicare Population [abstract]","volume":"33","author":"Weintraub","year":"2018","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.prdoa.2024.100256_b0170","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/ane.12201","article-title":"Parkinson's disease and risk of mortality: meta-analysis and systematic review","volume":"129","author":"Xu","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"13","key":"10.1016\/j.prdoa.2024.100256_b0175","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/mds.25898","article-title":"Mortality in Parkinson's disease: a systematic review and meta-analysis","volume":"29","author":"Macleod","year":"2014","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.prdoa.2024.100256_b0180","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/jnnp.68.2.254","article-title":"Mortality from Parkinson's disease","volume":"68","author":"Clarke","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"20","key":"10.1016\/j.prdoa.2024.100256_b0185","doi-asserted-by":"crossref","first-page":"e1986","DOI":"10.1212\/WNL.0000000000012826","article-title":"Trends in Mortality From Parkinson Disease in the United States, 1999\u20132019","volume":"97","author":"Rong","year":"2021","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.prdoa.2024.100256_b0190","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archneurol.2009.221","article-title":"Clinical features in early Parkinson disease and survival","volume":"66","author":"Lo","year":"2009","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.prdoa.2024.100256_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11940-013-0281-2","article-title":"Treatment of psychosis and dementia in Parkinson\u2019s disease","volume":"16","author":"Goldman","year":"2014","journal-title":"Curr. Treat. Options. Neurol."},{"issue":"6","key":"10.1016\/j.prdoa.2024.100256_b0200","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/jnnp-2020-323939","article-title":"Prognostic predictors relevant to end-of-life palliative care in Parkinson's disease and related disorders: a systematic review","volume":"92","author":"Akbar","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.prdoa.2024.100256_b0205","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"9916","key":"10.1016\/j.prdoa.2024.100256_b0210","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.prdoa.2024.100256_b0215","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.4088\/JCP.16r11119","article-title":"The US Food and Drug Administration's perspective on the new antipsychotic pimavanserin","volume":"78","author":"Mathis","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.prdoa.2024.100256_b0220","unstructured":"FDA. APPLICATION NUMBER: 207318Orig1s000. 2015 [cited 2023 Oct 30]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/207318Orig1s000MedR.pdf."},{"key":"10.1016\/j.prdoa.2024.100256_b0225","unstructured":"FDA Food and Drug Administration, FDA Briefing Document: Psychopharmacologic Drugs Advisory Committee (PDAC) Meeting, 2016. Available at: https:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterialsDrugs\/PsychopharmacologicalDrugsAdvisoryCommittee\/ucm492451.htm (acccessed February 12, 2019). 2016."},{"issue":"2","key":"10.1016\/j.prdoa.2024.100256_b0230","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/JGP.0b013e3182051bd6","article-title":"Antipsychotics and mortality in Parkinsonism","volume":"20","author":"Marras","year":"2012","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"8","key":"10.1016\/j.prdoa.2024.100256_b0235","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/appi.ajp.21090876","article-title":"Mortality among Parkinson's disease patients treated with pimavanserin or atypical antipsychotics: an observational study in medicare beneficiaries","volume":"179","author":"Mosholder","year":"2022","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.prdoa.2024.100256_b0240","first-page":"1","article-title":"Mortality in patients with Parkinson's disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: A cohort study","volume":"46","author":"Layton","year":"2022","journal-title":"Drug Saf."},{"issue":"3","key":"10.1016\/j.prdoa.2024.100256_b0245","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mdc3.13652","article-title":"Comparison of pimavanserin versus quetiapine for hospitalization and mortality risk among medicare beneficiaries with Parkinson\u2019s disease psychosis","volume":"10","author":"Alipour-Harris","year":"2023","journal-title":"Movement Disorders Clinical Practice"},{"key":"10.1016\/j.prdoa.2024.100256_b0250","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.parkreldis.2019.11.009","article-title":"Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies","volume":"69","author":"Horn","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2024.100256_b0255","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2022.08.013","article-title":"Atypical antipsychotic use and mortality risk in Parkinson disease","volume":"103","author":"Nguyen","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"issue":"13","key":"10.1016\/j.prdoa.2024.100256_b0260","doi-asserted-by":"crossref","first-page":"e1266","DOI":"10.1212\/WNL.0000000000012601","article-title":"Risk of hospitalization and death associated with pimavanserin use in older adults with Parkinson disease","volume":"97","author":"Hwang","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.prdoa.2024.100256_b0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278262","article-title":"Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis","volume":"18","author":"Longardner","year":"2023","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.prdoa.2024.100256_b0270","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1212\/WNL.0000000000006396","article-title":"Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine","volume":"91","author":"Moreno","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.prdoa.2024.100256_b0275","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/mds.20881","article-title":"Survival of Parkinson's disease patients in a large prospective cohort of male health professionals","volume":"21","author":"Chen","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2024.100256_b0280","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.parkreldis.2020.06.026","article-title":"Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis","volume":"77","author":"Ballard","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"issue":"10","key":"10.1016\/j.prdoa.2024.100256_b0285","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jamda.2015.06.021","article-title":"Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis","volume":"16","author":"Ballard","year":"2015","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.prdoa.2024.100256_b0290","first-page":"3256542","article-title":"Management of psychosis in Parkinson's disease: emphasizing clinical subtypes and pathophysiological mechanisms of the condition","volume":"2017","author":"Taddei","year":"2017","journal-title":"Parkinsons Dis"},{"issue":"2","key":"10.1016\/j.prdoa.2024.100256_b0295","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phen ylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.prdoa.2024.100256_b0300","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease\u2014an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2024.100256_b0305","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.parkreldis.2020.07.021","article-title":"Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: A systematic review and Bayesian network meta-analysis","volume":"78","author":"Iketani","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2024.100256_b0310","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2147\/NDT.S201029","article-title":"Atypical antipsychotics for Parkinson's disease psychosis: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"11","key":"10.1016\/j.prdoa.2024.100256_b0315","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/gps.5381","article-title":"Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis","volume":"35","author":"Ballard","year":"2020","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.prdoa.2024.100256_b0320","doi-asserted-by":"crossref","DOI":"10.1177\/08919887231154933","article-title":"Comparative efficacy, safety, and acceptability of pimavanserin and other atypical antipsychotics for Parkinson\u2019s disease psychosis: systematic review and network meta-analysis","author":"Yunusa","year":"2023","journal-title":"J. Geriatr. Psychiatry Neurol."},{"issue":"1\u20133","key":"10.1016\/j.prdoa.2024.100256_b0325","first-page":"46","article-title":"Pimavanserin in the treatment of Parkinson\u2019s disease psychosis: meta-analysis and meta-regression of randomized clinical trials","volume":"19","author":"Mansuri","year":"2022","journal-title":"Innovations in Clinical Neuroscience"},{"issue":"1","key":"10.1016\/j.prdoa.2024.100256_b0330","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/13696998.2022.2152600","article-title":"Health care resource utilization patterns among patients with Parkinson\u2019s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics","volume":"26","author":"Rajagopalan","year":"2023","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.prdoa.2024.100256_b0335","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40801-021-00284-1","article-title":"Falls and fractures in patients with Parkinson\u2019s disease-related psychosis treated with pimavanserin vs atypical antipsychotics: a cohort study","volume":"9","author":"Layton","year":"2021","journal-title":"Drugs Real World Outcomes"}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112524000276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112524000276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T21:56:48Z","timestamp":1718575008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112524000276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":67,"alternative-id":["S2590112524000276"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2024.100256","relation":{},"ISSN":["2590-1125"],"issn-type":[{"type":"print","value":"2590-1125"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2024.100256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100256"}}